cas 551921-19-8|| where to buy 4-methyl-3-[3-pyridin-3-yl-6-(trifluoromethyl)thieno[3,2-b]pyridin-2-yl]-1H-1,2,4-triazole-5-thione

Produktname:4-methyl-3-[3-pyridin-3-yl-6-(trifluoromethyl)thieno[3,2-b]pyridin-2-yl]-1H-1,2,4-triazole-5-thione

IUPAC Name:4-methyl-3-[3-(pyridin-3-yl)-6-(trifluoromethyl)thieno[3,2-b]pyridin-2-yl]-4,5-dihydro-1H-1,2,4-triazole-5-thione

: CAS：551921-19-8; Molekulare Formel：C16H10F3N5S2; Reinheit：95%+

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 551921-19-8 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:551921-19-8; Molekulare Formel:C16H10F3N5S2; Schmelzpunkt:-; SMILES-Code:CN1C(=S)NN=C1C1=C(C2=NC=C(C=C2S1)C(F)(F)F)C1=CC=CN=C1; Dichte:

: Katalognummer:CM712552; Molekulargewicht:393.41; Siedepunkt:; Mdl-Nr.:MFCD01315037; Lagerung:

: Triazoles; Triazole refers to a heterocyclic compound with the molecular formula C2H3N3, which has a five-membered ring consisting of two carbon atoms and three nitrogen atoms. Neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease already affect many people around the world, and these numbers are increasing rapidly. Treatment for these disorders is often aimed at relieving symptoms and has no cure. Research on new molecules is underway, and heterocyclic compounds have important pharmacological implications. Triazoles and tetrazoles are emerging as new molecules in this field.

: Thienopyridines; Thienopyridines are similar in structure to quinoline and isoquinoline, and are a class of heterocyclic compounds with important physiological activity and medicinal value. Thienopyridines are a subclass of antiplatelet drugs that prevent platelet aggregation by binding to selected extracellular cysteine residues on the P2Y12 receptor located on the platelet membrane.